(CRIS) Curis, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CRIS) Curis, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Curis, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotion tactics to show how it competes and reaches customers. The page includes a real preview/sample of the analysis so you can evaluate style and content before buying; purchase the full version to receive the complete ready-to-use report.
Product
Emavusertib Phase 1/2
Emavusertib is Curis, Inc.'s lead oncology asset by development stage, an oral small molecule in clinical-stage testing. It is in Phase 1/2 studies for non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes, giving Curis a multi-indication pipeline driver. The asset supports the Product and Promotion side of Curis’s 4P mix by pairing a convenient oral format with late early-stage clinical momentum.
CI-8993 VISTA Antibody
CI-8993 is a monoclonal antibody program built to block V-domain Ig suppressor of T cell activation, or VISTA, a checkpoint tied to immune evasion. It fits Curis, Inc.'s immuno-oncology focus by targeting a high-value pathway in cancer care, but it remains a development-stage asset, not a marketed product.
For the 2025/2026 period, its value sits in pipeline optionality: if VISTA blockade shows clinical signal, it could expand Curis, Inc.'s shot at combination therapy deals and future oncology revenue.
Fimepinostat HDAC PI3K
Curis, Inc.'s Fimepinostat is an oral dual HDAC and PI3K inhibitor aimed at MYC-altered diffuse large B-cell lymphoma, a biomarker-defined cancer subgroup. The product strategy is tight: target a clear genetic marker, focus on a hard-to-treat blood cancer, and use an oral format that can support outpatient use.
CA-170 and CA-327
CA-170 is Curis, Inc.’s oral small molecule for advanced solid tumors and lymphomas, while CA-327 is still in the pre-IND phase. Together, they widen Curis, Inc.’s pipeline beyond its lead hematology assets and give the company more shots at data-driven catalysts.
In Product terms, these programs target distinct cancer settings and support a broader development story. CA-170 is the nearer-term clinical asset, and CA-327 adds early-stage optionality.
- CA-170: oral oncology small molecule
- Targets solid tumors and lymphomas
- CA-327: pre-IND stage
- Broadens Curis, Inc. pipeline
Erivedge Hedgehog Inhibitor
Erivedge is Curis, Inc.’s oral hedgehog-pathway inhibitor for advanced basal cell carcinoma, a cancer where Hedgehog signaling is active in over 90% of cases. Curis markets it with F. Hoffmann-La Roche Ltd. and Genentech Inc., so product reach depends on that partnered commercial setup.
In the 4P mix, Product is a targeted small-molecule therapy with a clear niche and specialty-use profile; place and promotion are largely partner-led, while price is tied to oncology reimbursement and access rules.
- Target: advanced basal cell carcinoma
- Route: oral, once-daily therapy
- Mechanism: hedgehog pathway inhibition
- Partnered with Roche and Genentech
Curis’ Oncology Pipeline Anchored by Emavusertib and Erivedge
Curis, Inc.'s Product mix is built around oncology pipeline assets, led by emavusertib, a clinical-stage oral small molecule in Phase 1/2 for NHL, AML, and MDS. Fimepinostat, CA-170, and CA-327 add biomarker-led and early-stage optionality, while Erivedge remains a partnered, marketed niche therapy in advanced basal cell carcinoma.
| Asset | Stage | Key use |
|---|---|---|
| Emavusertib | Phase 1/2 | NHL, AML, MDS |
| Erivedge | Marketed | Advanced BCC |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific breakdown of Curis, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Quickly clarifies Curis, Inc.’s 4Ps, easing analysis overload and supporting fast, confident decisions.
Reference Sources
Provides a concise, traceable list of primary and reputable sources to validate Curis, Inc. assumptions and speed investor due diligence.
Place
Lexington Massachusetts HQ
Curis, Inc. is headquartered in Lexington, Massachusetts, and that site serves as its corporate base. Strategic, scientific, and administrative work is directed there, keeping leadership and R&D close to the Boston biotech cluster. For a biotech company, a single HQ helps keep decision-making fast and operating costs tight.
United States Clinical Focus
Curis, Inc. keeps its United States clinical focus tight: its cancer pipeline is built around U.S.-based, clinical-stage development, so trials, data readouts, and investigator sites are centered in American oncology centers. That gives the company direct access to the U.S. research base and the FDA path for future commercialization. In practice, its market reach is mainly shaped by U.S. trial execution, regulatory milestones, and oncology partner networks.
Trial Site Network
Curis, Inc. relies on hospital and research sites to move emavusertib and its other clinical programs, so the trial network is the main place where these development-stage products reach patients. In its 2024 pipeline, emavusertib was still in Phase 1/2 studies, which means site access, investigator enrollment, and trial execution drive progress more than retail distribution. The tighter the site network, the faster Curis can recruit and generate data for each study.
Roche Genentech Channel
Curis uses a partner-led place strategy for Erivedge: Roche and Genentech handle co-development and commercialization, while Curis does not rely on direct retail distribution. Erivedge was FDA-approved in 2012, and this channel keeps access tied to Roche Genentech’s oncology network rather than Curis-owned sales routes.
- Roche Genentech runs commercialization
- Curis avoids direct retail distribution
- Erivedge approval year: 2012
Aurigene Collaboration Route
Curis, Inc. uses the Aurigene Discovery Technologies Limited partnership as an external route for small molecule research, development, and possible commercialization, which lowers in-house burden and widens its development reach. The setup gives Curis a partner-led path to advance assets beyond discovery while sharing execution risk and market access.
- External R&D support
- Small molecule focus
- Shared development risk
- Commercial pathway access
Curis Stays Lean in Lexington, Reaching Patients Through Partners
Curis, Inc. keeps Place centered on one U.S. base: Lexington, Massachusetts, while its clinical work stays in U.S. oncology sites. That supports fast coordination, FDA-facing trials, and tight control of a small biotech footprint.
For market access, Curis uses partners, not a broad sales network: Roche Genentech commercializes Erivedge, approved in 2012, and Aurigene supports external R&D. So its reach comes from trial sites and partner channels, not owned distribution.
| Place lever | Latest fact |
|---|---|
| HQ | Lexington, Massachusetts |
| Erivedge | FDA-approved 2012; Roche Genentech commercializes |
| Pipeline access | U.S. oncology trial sites |
Get Your Copy
Curis, Inc. Reference Sources
The preview shown here is the actual Curis, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully detailed, editable, and ready to use with no surprises.
Promotion
SEC Filings
Curis, Inc. uses SEC filings as its main investor promotion channel, with Form 10-K, 10-Q, and 8-K disclosures showing pipeline progress, collaboration terms, and financial results. These filings give analysts the hard data they need on cash use, operating losses, and program status, so they matter more than ads or broad brand campaigns. For a small biotech, that disclosure stream is a core promotion tool for trust and valuation.
Clinical Trial Updates
Curis, Inc. uses clinical trial updates to show pipeline progress, especially from its Phase 1/2 work and any pre-IND milestones. In biotech, even one new readout can matter because it helps de-risk a program and signal scientific momentum. That message is critical for investors, since development-stage value often hinges on clinical data, not sales.
Press Releases
Curis uses press releases to announce research and partnership updates, with a focus on product candidates like emavusertib and key strategic agreements. The company uses these notices to keep investors informed about pipeline activity and trial progress, which matters for a small biotech with limited revenue. In 2025, that kind of communication is still a core way Curis signals development milestones and partner news.
Partner Announcements
Curis, Inc. uses partner announcements with Roche, Genentech, and Aurigene as public promotion assets. These 3 collaborations widen reach and add third-party credibility, which helps Curis signal scientific validation without heavy paid media. They also show Curis can advance compounds through external alliances, a key proof point for a small biotech.
- 3 named partner collaborations
- Boosts credibility and reach
- Signals alliance-driven progress
Investor Relations
Curis’s promotion is investor-facing, not consumer-led: it speaks to shareholders, analysts, and oncology specialists, which fits a clinical-stage biotech model. Investor relations is the main channel for news on pipeline progress, trial data, and financing needs, since value depends on clinical milestones more than product ads. That makes the message B2B, evidence-based, and tied to capital-markets credibility.
- Targets investors and analysts
- Focuses on pipeline updates
- Supports biotech funding needs
- Builds trust through disclosures
Curis Relies on SEC Filings and Trial News to Win Investors
Curis, Inc.’s promotion is investor-led: SEC filings, trial updates, and press releases carry the message on pipeline progress, cash use, and partnership news. In 2025, this matters more than brand ads because value depends on clinical data, not sales. The company also uses partner names like Roche, Genentech, and Aurigene to add credibility.
| Promotion | Role |
|---|---|
| SEC filings | Core investor channel |
| Trial news | Signals de-risking |
Price
No Public List Prices
Curis, Inc.’s pipeline assets—Emavusertib, CI-8993, Fimepinostat, CA-170, and CA-327—are still investigational, so no public consumer list prices are disclosed. Pricing is not set like a retail product during development; it depends on trial results, FDA approval, dosing, and reimbursement. Curis reported $2.0 million in total revenue for 2025, underscoring that these candidates are not yet commercial products.
Partner-Sold Erivedge
Erivedge is co-developed and co-marketed with Roche and Genentech, so commercial pricing sits with the partnered oncology channel, not Curis. Curis is not a direct consumer seller for this product, which limits its control over list price, discounts, and access terms. In Curis filings, Erivedge remains a partnered asset rather than a company-run retail product.
Development Stage Economics
Curis’s price is really a valuation of clinical progress, not unit sales, because the Company still has no approved product revenue. In 2025, its economics were driven by R&D spend, trial readouts, and the chance of moving compounds to later-stage milestones. So the market prices Curis on pipeline value, cash runway, and de-risking events, not shelf pricing.
Collaboration-Based Revenue
Curis, Inc. uses collaboration-based revenue because it is a small clinical-stage biotech with no broad product sales base. Licensing, co-development, and commercialization deals are the main way it turns science into cash, so partner payments and milestones matter more than volume sales.
That model fits the sector: many early biotechs trade future upside for lower upfront risk and outside funding. For Curis, the revenue stream is tied to deal terms, program progress, and partner execution, so cash flow can swing sharply by quarter.
- Licensing drives monetization
- Co-development shares risk
- Milestones can move revenue
- Partner execution affects cash flow
Oncology Reimbursement Path
Oncology pricing is mostly set by payer coverage, prior auth, and site-of-care rules, so a launch can face high rebates and tight access. Cancer drugs are often routed through specialty pharmacy or hospital outpatient channels; in the U.S., oncology spend was about $230B in 2024, showing how reimbursement drives net price. Curis, Inc.’s pipeline is still pre-broad-commercial, so no market pricing has been established yet.
- Access drives net price
- Specialty channels are common
- Curis, Inc. has no launch price yet
Curis Has No Set Launch Price Yet
Curis, Inc. has no set launch price yet because its pipeline remains investigational, so price is tied to trial progress, FDA approval, and payer access. In 2025, Curis reported $2.0 million of total revenue, showing it still has no commercial product pricing. Erivedge is partnered with Roche and Genentech, so pricing there sits with the partner channel, not Curis.
| Price factor | Curis, Inc. |
|---|---|
| 2025 revenue | $2.0 million |
| Launch pricing | Not established |
| Erivedge pricing control | Partnered |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.